Kornimate/medical-research-clean huggingface dataset:
the effects of administration of combined docosahexaenoic acid and vitamin e supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia

Conditions: Asthenozoospermia

Summary: since docosahexaenoic acid (dha) level in sperm membrane has been shown to be decreased in asthenozoospermic men, the investigators hypothesized that dha supplementation may improve it. furthermore, the investigators added vitamin e to it to protect its unsaturated bonds which are susceptible to oxidation and production of free oxygen radicals.


Eligibility criteria:
inclusion criteria: * willing to participate in the study and filling out the informed consent form * should be infertile (no conception after 12 months intercourse without any contraception) * age 20-45 y.o, idiopathic asthenospermia according to who criteria * normal hormonal profile exclusion criteria: * any infection in genitourinary (gu) tract * any anatomical abnormality in gu tract * any chronic disease during last 3 months * any surgery in gu tract * consumption of omega-3 fatty acids and/or vitamin e supplements during last 3 months
observation of clinical consistency of organoid-chips drug sensitivity in chemotherapy for pca with visceral metastasis

Conditions: Prostate Cancer; Organoid

Summary: this project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans.

this project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans;the final medication regimen for patients is determined by doctors based on their experience and in vitro drug sensitivity results. the actual clinical efficacy of medication is tracked for patients, and the organoid chip drug sensitivity detection model is analyzed as a predictor of the sensitivity, specificity, and accuracy of anti-tumor chemotherapy drugs, providing data reference for clinical applications.at the same time, analyze the accuracy of drug sensitivity testing results and clinical empirical medication.if patients are treated with a chemotherapy combined with immunotherapy regimen, the in vitro sensitivity of immune drugs will be determined using organoid-immune co-culture technology, and exploratory research on the predictive performance of immune models will be conducted in conjunction with clinical medication.

Eligibility criteria:
inclusion criteria: 1. patients with visceral metastasis of prostate cancer diagnosed clinically or pathologically; 2. age ≥ 18 years old; 3. ecog score ≤ 2 points or ecog score 3-4 points due to tumor progression; 4. normal liver and kidney function, serum transaminase alt\<66 u/l, ast\<36 u/l, total bilirubin\<22 umol/l, creatinine\<106 umol/l, urea nitrogen\<6.1 mmol/l; normal bone marrow function: neutrophil count ≥ 1800/mm3 and platelet count ≥ 100000/mm3; 5. can obtain surgical or biopsy samples; 6. patients voluntarily join this study and sign an informed consent form. exclusion criteria: 1. patients with severe heart, liver, kidney, and peripheral nervous system diseases, as well as autoimmune diseases such as hyperthyroidism and hypothyroidism; systemic lupus erythematosus, etc; 2. patients who are unable to obtain tissue samples; 3. subjects with active pulmonary tuberculosis (tb); 4. subjects who are preparing for or have previously undergone tissue/organ transplantation; 5. exclusion criteria are not listed, but the researchers believe that patients who are not suitable to participate in this clinical study.
cognitive effects of nimodipine in patients with schizophrenia

Conditions: Schizophrenia; Schizo Affective Disorder

Summary: this study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.the subjects will also complete a 30-minute structural and functional mri scan, with the goal of linking brain activity with working memory performance. investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the a allele for the calcium voltage-gated channel subunit alpha1 c (cacna1c) risk single nucleotide polymorphism (snp) (rs1006737) in comparison to the response of g carriers.

the main cognitive task of interest in this study is the n-back task because of the observed attenuation of prefrontal and parietal cortical activity after nimodipine administration in healthy subjects. investigators hypothesize that acute nimodipine administration will improve cortical activation, which will lead to improved cognitive performance. the current study will provide insight whether nimodipine or another calcium channel blocker could be used as a treatment approach to alleviate cognitive deficits in patients with schizophrenia.

Eligibility criteria:
inclusion criteria: * this study will recruit patients with schizophrenia and/or schizoaffective disorder exclusion criteria: * past or current neurological disorder (including stroke, brain tumor, epilepsy, alzheimer's, parkinson's or huntington's disease) * uncontrolled medical disorder * current or past hypotension * head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma * positive pregnancy test, or currently breast feeding * having an adverse reaction to nimodipine, or other calcium channel blocker
the 1200 patients project: studying the implementation of clinical pharmacogenomic testing

Conditions: Patients Undergoing Routine Health Care; Heart Diseases; Inflammatory Bowel Diseases; Autoimmune Disease; Inflammatory Disease; Blood Coagulation Disorders; Hepatitis C; Non-Metastatic Neoplasm

Summary: the purpose of this study is to collect dna samples from patients undergoing routine care at the university of chicago. these samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. the results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.


Eligibility criteria:
inclusion criteria: * receiving ongoing, out-patient care at the university of chicago medical center under the routine care of a physician participating in this trial * life expectancy of at least 3 years * must be 18 years or older * must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment or be 65 years or older or be reasonably expected to require the use of a prescription medication within the next 5 years * patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to: * patients requiring specialized cardiology care * patients with inflammatory bowel diseases * patients with systemic autoimmune or inflammatory diseases * patients requiring long-term oral anticoagulation * patients with hepatitis c * patients with non-metastatic cancer exclusion criteria: * patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years. * patients who have undergone, or are being actively considered for, liver or kidney transplantation. * inability to understand and give informed consent to participate.
study of autologous neo-bladder construct in subjects with neurogenic bladder following spinal cord injury

Conditions: Neurogenic Bladder

Summary: subjects with neurogenic bladder secondary to spinal cord injury that is refractory to medical treatment and requires augmentation cystoplasty will be enrolled. the hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will reduce maximum detrusor pressure.


Eligibility criteria:
inclusion criteria: * subjects with neurogenic bladders secondary to spinal cord injury exclusion criteria: * prior augmentation procedures or urinary diversion * recent urologic or intraperitoneal surgery or device implantation * recent history of spinal cord injury of less than a year * recent neurologic surgery * requirement for concomitant urological surgical procedures
washed microbiota transplantation for tourette's syndrome

Conditions: Tourette Syndrome

Summary: this study aimed to evaluate the efficacy of washed microbiota transplantation in the treatment of tourette's syndrome (ts).

emerging scientific data support the significant role of microbiota in the modulation of the central nervous system. the reconstitution of gut microbiota might be a potential option to treat tourette's syndrome (ts). fmt has been reported to be a highly effective therapy to restore the gut microbiota dysbiosis by transferring gut microbiota from healthy donors to patients. the newly improved methodology of fmt based on the automatic washing process and the related delivering consideration was named as washed microbiota transplantation (wmt) by the fmt-standardization study group. fmt has shown treatment potential in several gut-brain axis-related disorders, such as amyotrophic lateral sclerosis and parkinson's disease, promoting us to investigate its treatment potential for tourette's syndrome. in this study, investigators aimed to evaluate the efficacy of wmt for tourette's syndrome and its comorbidities using specialized questionnaires for tourette's syndrome and investigate the underlying mechanism.

Eligibility criteria:
inclusion criteria: 1. patients were aged 6 to 17 years (inclusive); 2. met the diagnostic and statistical manual of mental disorders, fifth edition criteria for ts; 3. had a yale global tic severity scale-total tic score (ygtss-tts) of at least 20 at screening and baseline. 4. underwent wmt. exclusion criteria: 1. complicated with certain brain disease, including tumor,injury,cerebrovascular disease; 2. complicated with other severe disease, including cancers, organ failure, heart diseases; 3. stereotypy associated with autism spectrum disorder; 4. with a confirmed diagnosis of psychiatric diseases, such as bipolar disorders; schizophrenia and major depressive disorders; 5. clinically significant obsessive-compulsive disorder at baseline considered to be the primary cause of impairment at baseline; 6. medications use affecting gut microbiota such as antibiotics and probiotics three months before wmt. 7. other neurologic disorders other than ts that could influence the evaluation of tics.

Keywords: tic disorders gut microbiota brain-gut axis washed microbiota transplantation tourette syndrome
the relationship between white matter hyperintensity with cognition and emotion

Conditions: Aged; Leukoaraiosis

Summary: white matter hyperintensity (wmh) has been found to be related with cognitive and emotional dysfunction. a presumed mechanism is that wmh disrupts the structural connectivity within a large-scale brain network, thereby impairing the brain's ability to integrate the neural processes efficiently. it is not yet clear, what the pattern of brain network disruption relates to wmh and how the brain network disruption induced by wmh has an effect on cognition and emotion performance. using multi-model magnetic resonance imaging (mri) techniques, we aimed to explore the mechanisms of cognitive decline and depression related with brain network dysfunction in patients with wmh, and to provide objective imaging marker for early diagnosis and prevention of wmh associated cognitive decline and depression.


Eligibility criteria:
inclusion criteria: 1. white matter hyperintensity visible on t2 fluid-attenuated inversion recovery images; 2. age between 35 to 80 years; 3. without stroke lesion (except lacunar infarction) on current diffusion weighted images; 4. without a history of multiple sclerosis, alzheimer's disease, parkinson's disease and head trauma. exclusion criteria: 1. white matter lesions of nonvascular origin (immunological-demyelinating, metabolic, toxic, infectious, other); 2. intracranial hemorrhage; 3. with severe head motion on magnetic resonance images

Keywords: white matter hyperintensity brain network mri cognition emotion
a randomized, controlled trial of the effectiveness of perioperative antibiotics for reduction of burn wound bacterial concentration following grafting

Conditions: Burn; Surgery; Infection Wound

Summary: the purpose of this study if to evaluate the effectiveness of prophylactic antibiotics given during surgery in reducing the concentration of bacteria in a burn wound after surgery.

this is a single-blind, randomized, controlled study to assess the effectiveness and safety of prophylactic perioperative administration of antibiotics for the reduction of bacterial concentration in burn wounds. subjects who meet enrollment criteria will be randomized in a 1:1 ratio to receive either perioperative prophylaxis with intravenous antibiotics or institutional standard of care, consisting of no antibiotic therapy. this with be a single center study. following randomization, patients will receive their assigned treatment (antibiotics or standard of care) after induction of anesthesia, no more than one hour prior to incision. patients weighing 120 kg or less will receive 2 grams of intravenous cefazolin, with those weighing \> 120 kg receiving 3 grams intravenous cefazolin. re-dosing will occur every 4 hours that the patient remains in the operating room. for patients with a documented beta-lactam allergy, clindamycin 900 mg will be given intravenously with re-dosing every 6 hours that the patient remains in the operating room. patients with allergies to both agents will be excluded from the study. biological samples will be obtained at three primary time-points: intraoperatively, at the time of the initial postoperative dressing take-down (within six hours), and at the time of a single follow up visit (10-28 days postoperatively).

Eligibility criteria:
inclusion criteria: 1. subject age ≥ 18 years old at the time of consent 2. burn wound sustained less than 48 hours prior to the time of presentation to medstar washington hospital center 3. burn wounds solely due to a thermal mechanism 4. total body surface area burned ≤ 10% 5. anticipated to require a single grafting procedure 6. able to provide informed consent to participate exclusion criteria: 1. positive pregnancy test in females of child bearing age 2. antibiotic administration within 30 days prior to admission 3. known / documented beta lactam allergy and clindamycin allergy 4. presence of burn wound cellulitis or infection pre-operatively 5. intraoperative discovery of infection 6. incarceration 7. presence of factors that may affect wound healing, per clinician judgment, such as chronic malnutrition and immunocompromised state

Keywords: microbiome perioperative antibiotics autograft xenograft
adequacy of exsanguination between esmarch bandages and simple leg elevation in total knee arthroplasty

Conditions: Esmarch Bandages; Simple Leg Elevation

Summary: to compare the adequacy of exsanguination in the surgical field between the use of the esmarch bandages elevation and the simple leg elevation.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis of knee exclusion criteria: * there are deep vein thrombosis and pulmonary embolism * there are bleeding disorder,hypercoagulability,peripheral arterial disease and chronic venous insufficiency * take blood clotting pills * have had total knee arthroplasty * bmi \> 30
endobronchial ultrasound transbronchial needle aspiration of enlarged mediastinal in interstitial lung disease

Conditions: Interstitial Lung Disease

Summary: the aim of this study is to assess the findings of mediastinal/hilar ln sampling by ebus-tbna in patients with non-sarcoidosis interstitial lung disease ( ild) who demonstrate ln enlargement on chest imaging. patients with non-sarcoidosis ild referred for bronchoscopy will undergo ln sampling by ebus-tbna. cytology results will be recorded along with clinico-radiologic features, bal findings, histology and final ild diagnosis.


Eligibility criteria:
inclusion criteria: 1. non-sarcoidosis ild (low probably of sarcoidosis based on radiology), 2. referred for bronchoscopy (bal, tblb or tbcb) in the interventional pulmonology unit at sheba medical center 3. patients with ln enlargement ≥1 cm in short diameter at stations 2, 4, 7, 10 or 11 (ln stations accessible to ebus-tbna) exclusion criteria: 1. known ild 2. ild with no indication to bronchoscopy 3. contraindication to bronchoscopy .
construct validation of the biotica questionnaire

Conditions: Infectious Diseases and Manifestations

Summary: based on barriers identified in a systematic literature search, a self-report questionnaire called "biotica" has been developed by the research team to assess medication adherence barriers to oral ab. the purpose of the biotica-questionnaire is to detect individual barriers that prevent the optimal intake of oral ab and thus, lead to inadequate adherence or persistence to the regimen. a study is now needed to establish construct validity. correlation between the answers to the biotica-questionnaire and the electronically monitored intake of the oral ab will be analyzed in the general population.

global consumption of oral antibiotics (ab) is increasing, with 80% of all prescriptions in europe stemming from primary care, mostly against respiratory tract infections. adequate intake behavior (i.e. adherence) to oral ab is vital to prevent therapeutic failure, to reduce the risk of microbial resistance, to reduce health care consumption, medication waste and environmental pollution. however, non-adherence among oral ab users reaches rates of 21%-38% during an ab treatment course. to improve medication adherence, understanding patient barriers to treatment is crucial. based on barriers identified in a systematic literature search, a self-report questionnaire called "biotica" has been developed by the research team to assess medication adherence barriers to oral ab. the purpose of the biotica-questionnaire is to detect individual barriers that prevent the optimal intake of oral ab and thus, lead to inadequate adherence or persistence to the regimen. a study is now needed to establish construct validity (also called criterion, convergent or concurrent validity) that is, to generate evidence that the questionnaire measures what it is intended to. thus, the instrument under investigation (i.e. biotica-questionnaire) will be distributed at the same time as the targeted attribute (i.e. adherence to oral ab) will be electronically monitored in the general population. the correlation between the two measurements will be analyzed.

Eligibility criteria:
inclusion criteria: * is ≥ 18 years * has a prescription for an oral ab for 3-30 days * self-manages medication * is able to read and understand the german language * signs the informed consent form (icf) * accepts to record the intake of oral ab with the electronic device time4med™ exclusion criteria: * is cognitively impaired * is currently pregnant or actively trying to get pregnant

Keywords: adherence oral antibiotics electronic monitoring
impact of fsh dosage during ovarian stimulation for ivf/icsi in granulosa cells

Conditions: Ovarian Function Insufficiency; Fertility Issues; Infertility,Female; Infertility

Summary: to study the influence of different daily rec-fsh dosages (150 iu versus 300 iu), performed in the same patient in consecutive cycles, on the relation between fsh- and lh-receptors of the granulosa cells of the growing follicle.

this is a prospective cross-over study. investigators want to study the effect of different dosages of recombinant fsh in the same patient on the expression of the fsh- and lh-receptors in the granulosa cells and on the endocrine milieu in the blood and the follicular fluid. an improved understanding of the mechanism leading to progesterone elevation might initiate a change in the ovarian stimulation approach, thereby not only preventing progesterone elevation and its negative consequences on art (assisted reproductive technology) outcome, but also improving individualization of the ovarian stimulation treatment according to the patients' characteristics.

Eligibility criteria:
inclusion criteria: * desire to perform oocyte freezing for social fertility preservation, age 18 - 38 years * bmi of 18-32 kg/m2 * regular menstrual cycles with a length of 24-35 days * anti-muellerian-hormone levels between 1.3 - 6.25 ng/ml (ferraretti and gianaroli, 2014; calzada et al., 2019) exclusion criteria: * occurrence of ovarian hyperstimulation syndrome (ohss) * occurrence of poor ovarian response (afc \< 5 and amh \< 0,5ng/ml) in previous ovarian stimulation treatment (20) * polycystic ovary syndrome (pcos) (21)

Keywords: ovarian stimulation granulosa cells follicle stimulating hormone receptor luteinising hormone receptor elevated progesterone
the management of glucose control and hypoglycemic prevention using continuous glucose monitoring system in patients with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this study was designed to evaluate the glucose control and hypoglycemic prevention effect of using continuous glucose monitoring system(cgms) in patients with type 1 diabetes. this is a prospective randomized controlled, single-center clinical study. patients will randomized 1:1 to either cgms or conventional self-monitoring of blood glucose (smbg) group. after 12 weeks of applying the cgms sensors, the improvement of parameters collected from the cgms will be estimated in comparison with data collected from the smbg.


Eligibility criteria:
inclusion criteria: 1. male or female patients ages \>= 20 years 2. patients diagnosed with type 1 diabetes. 3. patients with glycated hemoglobin (hba1c) \> 8.0% within 6 months before screening 4. patients who agree to perform self blood glucose monitoring responsibly during the study period 5. patients diagnosed with type 1 diabetes minimum 3 months prior to recruitment exclusion criteria: 1. patients diagnosed with type 2 diabetes. 2. patients with chronic disease (excluding thyroid disorders in which thyroid function is controlled in the normal range), or psychiatric disease 3. patients who cannot use the device properly such as an illiterate person or foreigners 4. patients incapable of making decisions based on their own judgement and will 5. a person who may not participate in the study according to investigator's judgement
automated detection of metastatic bone disease on bone scintigraphy scans

Conditions: Metastatic Bone Tumor

Summary: bone scintigraphy scans are two dimensional medical images that are used heavily in nuclear medicine. the scans detect changes in bone metabolism with high sensitivity, yet it lacks the specificity to underlying causes. therefore, further imaging would be required to confirm the underlying cause. the aim of this study is to investigate whether deep learning can improve clinical decision based on bone scintigraphy scans.


Eligibility criteria:
inclusion criteria: * patients who underwent a bone scintigraphy scan that is available with the radiologic report between 2010-2018 exclusion criteria: * the lack of a bone scan, or corresponding radiologic report